ZyCov-DThe subject expert committee (SEC) of the Indian Drug Regulator is likely to take up Ahmedabad-based pharmaceutical major Zydus Cadila's application for emergency use approval to its Covid-19 vaccine this week.
Zydus had last week approached the Drug Controller General of India (DCGI) for emergency use approval to its three-dose Covid-19 vaccine ZyCoV-D.
“The rolling review has been done and now it will be put up before the SEC for its recommendations,” a senior government was quoted by Economic Times as saying.
“The meeting is likely to happen sometime this week," the official added.
The vaccine, if approved by the DCGI, will be the fifth vaccine to get Indian drug regulator's nod for use in India. The DCGI had earlier approved Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Russian Covid-19 vaccine Sputnik V and US-based Moderna's Covid jab.
Zydus developed the DNA based vaccine with the support of the Central government's Department of Biotechnology and the Indian Council of Medical Research (ICMR). The jab has shown 66.6 per cent efficacy in an interim study.
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.